CC-115
As of the edition of 20 October 2026, CC-115 is a small molecule: of no established status; acts on MTOR and PRKDC.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Blood and lymph; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2011 to now |